Wire · opportunities
FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next?
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 July 2026 · Fusion42 review
FDA advisers narrowly voted to add six peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax) to a compounding list, allowing specialty pharmacies to legally prepare them with a doctor's prescription, though the recommendation is non-binding and requires FDA sign-off. The decision reflects political pressure from HHS Secretary Kennedy and a deep divide between industry-backed advisers and FDA scientists, who unanimously opposed the additions citing lack of clinical data and quality control risks.
This Wire brief sits within Fusion42's coverage of Digital Health, and 9 sources have reported it between 23 Jul 2026 and 28 Jul 2026.
◆ ◆ The Wire takeaway
You now have a legal pathway to dispense peptides that the FDA's own scientists rejected—but only if you're a licensed compounding pharmacy with a doctor writing prescriptions. The political cover is there (Kennedy backs it), the market demand is proven (black market already booming), but quality control is still a crapshoot; someone needs to build the supply chain, testing, and clinical evidence these compounds don't currently have.
◆ Coverage
9 sources · first reported 23 Jul 2026 · latest 28 Jul 2026
◆ Related on Wire
◆ Topics